AMENDMENT TO

RULES COMMITTEE PRINT 118–10 OFFERED BY Ms. JAYAPAL OF WASHINGTON

At the end of subtitle C of title VII, add the following new section:

1	SEC. 7 FUNDING FOR CONDUCT OF CERTAIN TRIALS
2	RELATING TO CORBEVAX VACCINE.
3	(a) Authorization of Appropriations.—There is
4	authorized to be appropriated \$20,000,000 for the United
5	States Army Medical Research and Development Com-
6	mand, including any subordinate entity of such Command,
7	to conduct two phase-III clinical trials for the patent-free
8	and openly licensed Corbevax vaccine (one trial with re-
9	spect to the vaccine and one trial with respect to the boost-
10	er for such vaccine), for the purpose of gauging the effec-
11	tiveness and suitability of such vaccine and booster in re-
12	ducing hospitalization and transmission rates of COVID-
13	19.
14	(b) Funding.—
15	(1) Increase.—Notwithstanding the amounts
16	set forth in the funding tables in division D, the
17	amount authorized to be appropriated in section 210
18	for Research, Development, Test, and Evaluation,

1

Army, as specified in the corresponding funding

2 table in section 4201, for Medical Technology, line 3 026, is hereby increased by \$20,000,000. 4 (2) Offset.—Notwithstanding the amounts set 5 forth in the funding tables in division D, the amount authorized to be appropriated in section 301 for Op-6 7 erations and Maintenance, as specified in the corresponding funding table in section 4301, for admin-8 9 istration and service-wide activities, Office of the Secretary of Defense, line 490, is hereby reduced by 10 \$20,000,000. 11

